KBC Group NV Cuts Stake in Gilead Sciences, Inc. (GILD)

KBC Group NV lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 657,636 shares of the biopharmaceutical company’s stock after selling 635,245 shares during the period. KBC Group NV owned about 0.05% of Gilead Sciences worth $46,548,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after buying an additional 310,607 shares during the period. Parnassus Investments CA increased its stake in shares of Gilead Sciences by 37.4% during the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the period. Legal & General Group Plc increased its stake in shares of Gilead Sciences by 9.3% during the second quarter. Legal & General Group Plc now owns 7,004,455 shares of the biopharmaceutical company’s stock valued at $495,778,000 after buying an additional 596,992 shares during the period. APG Asset Management N.V. increased its stake in shares of Gilead Sciences by 16.7% during the first quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock valued at $402,319,000 after buying an additional 849,741 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Gilead Sciences by 25.7% during the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after buying an additional 1,066,172 shares during the period. Hedge funds and other institutional investors own 73.97% of the company’s stock.

Several equities analysts have recently commented on GILD shares. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Thursday, August 31st. Deutsche Bank AG restated a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a research note on Thursday, August 31st. Credit Suisse Group restated an “outperform” rating and set a $85.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price target on the stock in a research note on Monday, June 26th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $85.64.

TRADEMARK VIOLATION WARNING: “KBC Group NV Cuts Stake in Gilead Sciences, Inc. (GILD)” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://ledgergazette.com/2017/10/21/kbc-group-nv-cuts-stake-in-gilead-sciences-inc-gild.html.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 81.21 on Friday. The stock has a 50 day moving average price of $82.63 and a 200-day moving average price of $72.65. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market capitalization of $106.05 billion, a PE ratio of 8.82 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.08 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.74 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

In related news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the transaction, the insider

Several other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in shares of Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after buying an additional 310,607 shares during the period. Parnassus Investments CA increased its stake in shares of Gilead Sciences by 37.4% during the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the period. Legal & General Group Plc increased its stake in shares of Gilead Sciences by 9.3% during the second quarter. Legal & General Group Plc now owns 7,004,455 shares of the biopharmaceutical company’s stock valued at $495,778,000 after buying an additional 596,992 shares during the period. APG Asset Management N.V. increased its stake in shares of Gilead Sciences by 16.7% during the first quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock valued at $402,319,000 after buying an additional 849,741 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Gilead Sciences by 25.7% during the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after buying an additional 1,066,172 shares during the period. Hedge funds and other institutional investors own 73.97% of the company’s stock.

Several equities analysts have recently commented on GILD shares. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Thursday, August 31st. Deutsche Bank AG restated a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a research note on Thursday, August 31st. Credit Suisse Group restated an “outperform” rating and set a $85.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price target on the stock in a research note on Monday, June 26th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $85.64.

TRADEMARK VIOLATION WARNING: “KBC Group NV Cuts Stake in Gilead Sciences, Inc. (GILD)” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://ledgergazette.com/2017/10/21/kbc-group-nv-cuts-stake-in-gilead-sciences-inc-gild.html.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 81.21 on Friday. The stock has a 50 day moving average price of $82.63 and a 200-day moving average price of $72.65. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market capitalization of $106.05 billion, a PE ratio of 8.82 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.08 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.74 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.

In related news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 446,819 shares of company stock valued at $36,338,919. Company insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply